Form 8-K · Current report
IQVIA 8-K, filed Sep 9, 2026
- Filed
- CIK
- 0001478242
- Accession no.
- 0001193125-26-386633
Summary
IQVIA Holdings' subsidiary IQVIA Inc. priced $2 billion of senior notes due 2034 at 6.375% per annum, with proceeds intended to redeem in full its 5.000% senior notes due 2026, repay part of its revolving credit facility borrowings, and cover offering fees and expenses. The offering, sold privately to qualified institutional buyers under Rule 144A and to non-U.S. investors under Regulation S, is expected to close on or about September 23, 2026, subject to customary conditions.
Key points
- IQVIA Inc. entered a purchase agreement with the purchasers' representative for $2 billion aggregate principal of senior notes due 2034 bearing 6.375% interest.
- Proceeds are earmarked to redeem in full the issuer's Senior 5.000% Notes due 2026 and repay a portion of revolver indebtedness.
- Consummation of the offering is subject to market and other customary closing conditions.
- The notes were not registered under the Securities Act and were offered only via private placement.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 8.01Other Events
- 9.01Financial Statements and Exhibits
From the filing
Item 8.01 Other Events On September 9, 2026, IQVIA Holdings Inc. (the “Company”) issued a press release announcing that its wholly owned subsidiary, IQVIA Inc. (the “Issuer”), intends to raise $2,000,000,000 in gross proceeds through an offering of senior notes due 2034 (the “Notes Offering”) and intends to use the proceeds to redeem in full the Issuer’s Senior 5.000% Notes due 2026, to repay a portion of the outstanding indebtedness under the Issuer’s revolving credit facility and to pay fees and expenses related to the Notes Offering. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.